Clinical Research Directory
Browse clinical research sites, groups, and studies.
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Sponsor: Psoriasis Treatment Center of Central New Jersey
Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Official title: An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-01-16
Completion Date
2019-12-15
Last Updated
2019-02-04
Healthy Volunteers
No
Conditions
Interventions
Enstilar 0.005%-0.064% Topical Foam
Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Locations (1)
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States